- 関
- PGI2 receptor、prostacyclin receptor、prostaglandin I2 receptor
WordNet
- a cellular structure that is postulated to exist in order to mediate between a chemical agent that acts on nervous tissue and the physiological response
PrepTutorEJDIC
- =sense organ / 受信装置
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
English Journal
- Prostaglandin I2 and Prostaglandin E2 Modulate Human Intrarenal Artery Contractility Through Prostaglandin E2-EP4, Prostacyclin-IP, and Thromboxane A2-TP Receptors.
- Eskildsen MP1, Hansen PB1, Stubbe J1, Toft A1, Walter S1, Marcussen N1, Rasmussen LM1, Vanhoutte PM1, Jensen BL2.
- Hypertension.Hypertension.2014 Sep;64(3):551-6. doi: 10.1161/HYPERTENSIONAHA.113.03051. Epub 2014 Jun 9.
- Cyclooxygenase inhibitors decrease renal blood flow in settings with decreased effective circulating volume. The present study examined the hypothesis that prostaglandins, prostaglandin E2 (PGE2) and prostacyclin (PGI2), induce relaxation of human intrarenal arteries through PGE2-EP and PGI2-IP rece
- PMID 24914192
- Effect of prostaglandin I2 analogs on macrophage inflammatory protein 1α in human monocytes via I prostanoid receptor and cyclic adenosine monophosphate.
- Tsai MK1, Hsieh CC, Kuo HF, Yang SN, Kuo CH, Huang MY, Tsai YM, Lee MS, Hung CH.
- Journal of investigative medicine : the official publication of the American Federation for Clinical Research.J Investig Med.2014 Feb;62(2):332-9. doi: 10.231/JIM.0000000000000042.
- AIMS: Inflammation plays critical roles in atherosclerosis. Chemokines are responsible for leukocyte trafficking and involve in inflammatory diseases. Macrophage inflammatory protein 1α (MIP-1α) has been implicated in atherosclerotic lesion formation. Prostaglandin I2 (PGI2) analog, used in pulmon
- PMID 24402297
- Drug treatment of pulmonary hypertension in children.
- Vorhies EE1, Ivy DD.
- Paediatric drugs.Paediatr Drugs.2014 Feb;16(1):43-65. doi: 10.1007/s40272-013-0052-2.
- Pulmonary arterial hypertension (PAH) is a rare disease in infants and children that is associated with significant morbidity and mortality. The disease is characterized by progressive pulmonary vascular functional and structural changes resulting in increased pulmonary vascular resistance and event
- PMID 24114695
Japanese Journal
- 佐地 勉,中山 智孝,高月 晋一,池原 聡,嶋田 博光,直井 和之,佐藤 真理,松裏 裕行
- 日本小児循環器学会雑誌 31(4), 157-183, 2015
- 小児期PAHの薬物療法を行うにあたって，臨床医は小児は成人と異なり様々な特色があることを再認識しなければならない．すなわち，代謝酵素活性（p450など），受容体の濃度（密度）や感受性，器官の機能発達（特に腎臓と肝臓，心筋代謝），体脂肪の容積，蛋白（アルブミン）結合率，血中蛋白濃度，分散容積，薬物動態PKや薬力学PD，一定の年齢だけ反応する臓器（動脈管など），薬理遺伝子的背景， 遺伝子多型などによる …
- NAID 130005098178
- Pathological function of Ca2+-sensing receptor in pulmonary arterial hypertension
- Yamamura Aya
- Journal of Smooth Muscle Research 50(0), 8-17, 2014
- … In addition to Ca 2+ channel blockers (nifedipine, diltiazem), three categories of drug have been developed for the treatment of PAH based on the pathological mechanisms: prostacyclin and its analogues (epoprostenol, treprostinil, iloprost), endothelin receptor antagonists (bosentan, ambrisentan), and phosphodiesterase type 5 inhibitors (sildenafil, tadalafil). …
- NAID 130003391244
- Pulmonary hypertension associated with veno-occlusive disease in systemic sclerosis: Insight into the mechanism of resistance to vasodilator
- Tada Hayato,Konno Tetsuo,Aizu Motohiko,Yokawa Junichiro,Tsubokawa Toshinari,Fujii Hiroshi,Hayashi Kenshi,Uchiyama Katsuharu,Matsumura Masami,Kawano Mitsuhiro,Kawashiri Masa-aki,Yamagishi Masakazu
- Journal of Cardiology Cases 5(1), e44-e47, 2012-02
- … We report a case with pulmonary veno-occlusive disease (PVOD) associated with systemic sclerosis which exhibits strong resistance to pulmonary vasodilator.A 55-year-old female with severe pulmonary hypertension was admitted to our hospital to be introduced to epoprostenol infusion therapy. … Several aggressive treatments with pulmonary vasodilators, including oral prostaglandin, endothelin receptor antagonists, and phosphodiesterase 5 inhibitors, failed to improve her symptoms. …
- NAID 120003959455
Related Links
- prostacyclin [pros″tah-si´klin] a prostaglandin, PGI 2, synthesized by endothelial cells lining the walls of arteries and veins; it is a potent vasodilator and a potent inhibitor of platelet aggregation. When used pharmaceutically it is called epoprostenol
- Receptors, Epoprostenol: Cell surface receptors for EPOPROSTENOL. They are coupled to HETEROTRIMERIC G-PROTEINS.) ... Illness finder is a diagnostic medicine tool for educational purpose that looks up your patients' health ...
★リンクテーブル★
[★]
- 関
- epoprostenol receptor、prostacyclin receptor、prostaglandin I2 receptor
[★]
- 関
- epoprostenol receptor、PGI2 receptor、prostaglandin I2 receptor
[★]
- 関
- epoprostenol receptor、PGI2 receptor、prostacyclin receptor
[★]
- 英
- epoprostenol receptor
- 関
- プロスタサイクリン受容体、プロスタグランジンI2受容体
[★]
エポプロステノール